title: Direct stenting may limit myocardial injury during percutaneous coronary intervention.
abstract: BACKGROUND
  Direct coronary stenting has been shown to be safe and feasible, with a demonstrable reduction in cost, procedural time and radiation exposure. Direct stenting may limit distal embolization of atherosclerotic plaque and consequently reduce myocardial cell injury following percutaneous coronary intervention, which may have important prognostic implications.
  
  
  RESULTS
  We assessed cardiac troponin I (cTnI) release in the 24 hours following direct coronary stenting (DS) as compared to stenting with balloon predilatation (PD) in a total of 311 patients and 440 vessels/lesions (vessel to lesion ratio = 1:1) (DS: n = 107 patients and 149 vessels/lesions; PD: n = 204 patients and 291 vessels/lesions). The 2 groups were well matched except for a greater proportion of diabetic patients in the PD group (21%) compared to the DS group (11%) (p < 0.05). There were no significant differences in the distribution of target lesion site or angiographic complexity between the 2 groups. Primary angiographic success was achieved in 97% of vessels in the DS group and 98% of vessels in the PD group (p = NS). DS failed in 7/114 patients (6%) deemed suitable for DS by the operator, but all stents were subsequently successfully deployed following balloon predilatation. Abciximab (ReoPro , Eli Lilly Company, Indianapolis, Indiana) was used in 11 patients (10%) in the DS group and 24 patients (12%) in the PD group ( p = 0.68). The post-procedural median (IQR) peak cTnI concentrations were 0.2   0.1  g/L in the DS group and 0.5   0.3  g/L in the PD group (p = 0.02). Post-procedural cTnI concentrations were > 0.2  g/L in 11 patients (10%) in the DS group and in 53 patients (26%) in the PD group (X2 = 58.6; p < 0.0001). The rate of major adverse cardiac events at 6 18 month follow-up was 8% in the DS group and 15% in the PD group (X2 = 38.5; p = 0.02).
  
  
  CONCLUSIONS
  Direct stenting without balloon predilatation is associated with lower post-procedural cTnI concentrations and lower incidence of major adverse events compared to traditional stenting with predilatation.
authors.affiliation: King s College Hospital, Denmark, London, England, United Kingdom. tnageh@hotmail.com
authors.forename: Thuraia
authors.initials: T
authors.lastname: Nageh
authors.forename: Martyn R
authors.initials: MR
authors.lastname: Thomas
authors.forename: Roy A
authors.initials: RA
authors.lastname: Sherwood
authors.forename: Beverley M
authors.initials: BM
authors.lastname: Harris
authors.forename: David E
authors.initials: DE
authors.lastname: Jewitt
authors.forename: Ray J
authors.initials: RJ
authors.lastname: Wainwright
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007431:Intraoperative Complications / Q000209:etiology* / Q000378:metabolism*; D008131:London; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology* / Q000378:metabolism*; D015607:Stents; D019210:Troponin I / Q000378:metabolism
chemical_list: D019210:Troponin I